Immunohistochemical analysis demonstrated a significant converse correlation of FBXO16 and β‐catenin expression with increased levels of β‐catenin and concomitant attenuation of FBXO16 in higher grades of breast cancer patient samples (Figure 1E). This evidence concerns the gene FBXO16 and breast carcinoma.